These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38958)

  • 1. [Modulation of dopaminergic receptor sensitivity in the central nervous system: important parameters in synaptic function regulation].
    Costentin J
    Encephale; 1979; 5(2):121-49. PubMed ID: 38958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Experimental basis of the therapy of Parkinson's disease and the cholinergic-dopaminergic equilibrium in basal brain nuclei.
    Wolfarth S
    Pol J Pharmacol Pharm; 1976; 28(5):469-93. PubMed ID: 796834
    [No Abstract]   [Full Text] [Related]  

  • 3. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 4. The pathophysiology of tardive dyskinesia.
    Klawans HL; Carvey P; Tanner CM; Goetz CG
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synaptic and non-synaptic striatal dopamine D2 receptors: possible implications in normal and pathological behaviour.
    Korf J; Loopuijt LD
    Acta Morphol Neerl Scand; 1988-1989; 26(2-3):177-90. PubMed ID: 2908162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic drugs and their action on different neuronal pathways.
    Ungerstedt U; Herrera-Marschitz M; Forster C
    J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apomorphine stereotypies and transmitter mechanisms in the striatum. I. Changes in the apomorphine stereotypies caused by drugs acting on the GABA-ergic, dopaminergic and cholinergic transmission.
    Georgiev VP; Markovska VL; Petkova BP
    Acta Physiol Pharmacol Bulg; 1978; 4(3):56-64. PubMed ID: 220843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects of dopamine agonists and antagonists.
    Bianchine JR; Shaw GM; Greenwald JE; Dandalides SM
    Fed Proc; 1978 Aug; 37(10):2434-9. PubMed ID: 354976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Stereotyped behavior and the nigro-strio-nigral system].
    Arushanian EB
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1985; 35(5):819-32. PubMed ID: 2866641
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SCH23390 effects on apomorphine-induced responses of nigral dopaminergic neurons.
    Napier TC; Givens BS; Schulz DW; Bunney BS; Breese GR; Mailman RB
    J Pharmacol Exp Ther; 1986 Mar; 236(3):838-45. PubMed ID: 3512819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of dopaminergic and GABAergic neurotransmission: impact of 6-hydroxydopamine lesions into the substantia nigra of rats.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1995 Oct; 275(1):237-44. PubMed ID: 7562556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apomorphine stereotypies and transmitter mechanisms in the striatum. II. Interactions between GABA-ergic and cholinergic transmission.
    Georgiev VP; Petkova BP
    Acta Physiol Pharmacol Bulg; 1978; 4(3):65-70. PubMed ID: 220844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic and dopaminergic modulation of potassium conductances in neostriatal neurons.
    Kitai ST; Surmeier DJ
    Adv Neurol; 1993; 60():40-52. PubMed ID: 8380527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral correlates of dopaminergic supersensitivity.
    Iversen SD; Creese I
    Adv Neurol; 1975; 9():81-92. PubMed ID: 1170717
    [No Abstract]   [Full Text] [Related]  

  • 17. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
    Hársing LG; Vizi ES
    Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Problem of neuronal reception and the dopamine hypothesis of schizophrenia].
    Lideman RR; Zlobina GP; Mukhin AG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1980; 80(5):762-9. PubMed ID: 6106337
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.